There are currently 9 active clinical trials seeking participants for Idiopathic Pulmonary Fibrosis research studies. The states with the highest number of trials for Idiopathic Pulmonary Fibrosis participants are .
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
Recruiting
Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part. The purpose of this study is to find out how well BI 1839100 helps reduce coughing in people with IPF or PPF. Participants who have IPF are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1839100. Participants in 1 group get placebo. Placebo look... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +178 locations
Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
The study will evaluate the efficacy and safety of axatilimab in participants with IPF.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/21/2025
Locations: Royal Prince Alfred Hospital, Camperdown, New South Wales +73 locations
Conditions: Idiopathic Pulmonary Fibrosis
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Recruiting
The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in this patient population.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/21/2025
Locations: Research Site, Quilmes, Buenos Aires +80 locations
Conditions: Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Recruiting
This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550. The goal of this study is to find out how well people with pulmonary fibrosis tolerate long- term treatment with nerandomilast. The study also tests whether nerandomilast improves lung function and prolongs the time until symptoms get worse, participants need... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +370 locations
Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/07/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +503 locations
Conditions: Idiopathic Pulmonary Fibrosis
NAL ER IPF Respiratory Function and Safety Study
Recruiting
The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Mayo Clinic, Rochester, Minnesota +1 locations
Conditions: Idiopathic Pulmonary Fibrosis
A Study to Investigate Leramistat in Patients With IPF
Recruiting
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/16/2024
Locations: UCSF Fresno, Fresno, California +57 locations
Conditions: Idiopathic Pulmonary Fibrosis
Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole
Recruiting
IPF is a progressive scarring lung condition causing coughing and breathlessness. IPF patients often have reflux disease meaning stomach acid may be breathed into the lungs, potentially damaging them. Medicines which stop stomach acid production, proton pump inhibitors (PPIs), can be used to reduce reflux symptoms including heartburn. Some researchers suggest PPIs also reduce IPF progression. This research aims to see if IPF progresses slower if treated with PPIs. Based on the results, we will... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
12/15/2023
Locations: Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, Norfolk
Conditions: Idiopathic Pulmonary Fibrosis
Longitudinal Changes in Serum KL-6 in IPF
Recruiting
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with a poor prognosis. More accurate tests to predict disease progression and response to treatment are required. Krebs von den Lungen-6 (KL-6) is a blood marker associated with IPF. Results from previous studies have shown that levels of KL-6 are higher in patients with IPF compared to people without the disease. In addition, it is not clear what impact treatment has on KL-6 levels, and whether this could help us to monitor how effe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2023
Locations: Manchester University hospitals NHS Foundation Trust, Manchester, Not set
Conditions: Idiopathic Pulmonary Fibrosis